Quest PharmaTech strengthens its Antibody Immunotherapy Technology by licensing anti-MUC1 IgE Technology from Stanford University; Researchers to present late-breaking data at the 28th Annual Meeting of the Society for Immunotherapy of Cancer to be held November 8 – 10, 2013 in Maryland, U.S.
TSX Venture: QPT
EDMONTON, Nov. 7, 2013 /PRNewswire/ – Quest PharmaTech Inc. (TSX-V: QPT)
(“Quest” or the “Company”), a pharmaceutical company developing and
commercializing products for the treatment of cancer, announces the
presentation of a late-breaking abstract at the 28(th) Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on
November 9, 2013 in Maryland, U.S. The work was jointly developed by
Stanford University, AIT Strategies and Quest as continuation of an
exclusive license agreement between Stanford University and Quest to
develop and market anti-MUC1 IgE technology for the treatment of
The title of the presentation is “MUC1 Specific IgE to Modify Myeloid
Derived Cells of the Tumor Microenvironment”. The licensed technology
was developed by a team led by Joseph Mollick, M.D., Ph.D., formerly of
Stanford University, and covers the use of immunotherapeutic IgE in
development for treatment of patients with malignancies expressing the
tumor-associated antigen MUC1, which is associated with cancer of the
pancreas, colon, breast, lung, ovary, as well as multiple myeloma and
Dr, Mollick details the potential of the novel molecule to reprogram
myeloid cells in the tumor microenvironment, leading to elimination of
tumours and prevention of metastases. At the same time, the antibody
can activate specific cellular immune responses directed against MUC1
originating in the tumor.
Quest is focusing its commercial efforts in the area of antibody
mediated cancer immunotherapy with both IgG and IgE products. The
Company recently licensed an anti-PSA IgE technology from the
University of California at Los Angeles and Advanced Immune
Therapeutics, Inc. Quest is currently conducting preclinical studies on
anti-MUC1 IgE at the University of Nebraska Medical Center through a
sponsored research contract to Professor Michael A. Hollingsworth.
Quest also holds numerous patents for the use of tumor associated
monoclonal antibodies as immune modulators. “Both IgG and IgE
technologies are complementary and provide a novel approach for
enhancing the effectiveness of chemotherapy while activating specific
immunity to fight the cancer” commented Dr. Madi R. Madiyalakan, CEO of
About Quest PharmaTech Inc.
Quest PharmaTech is a publicly traded, Canadian based clinical stage
company developing a portfolio of product candidates for the treatment
of cancer by combining immunotherapeutic antibodies with chemotherapy,
immune-adjuvants and photodynamic therapy. Quest has a body of clinical
experience and a new appreciation of the obstacles and potential of
combinatorial immunotherapeutic approaches to cancer by using either
immunoglobulin G or E as immune modulators to enhance tumor specific
immunity and clinical outcome.
The most advanced of its product candidates is oregovomab, an anti-CA125
monoclonal antibody, in combination with front-line chemotherapy for
the treatment of advanced ovarian cancer which is currently undergoing
a phase IIb clinical trial in 12 centers in Italy and the U.S. The
Company’s MUC1 program that has already undergone a phase I clinical
trial has the potential to permit tumor specific immunization in more
than 70% of all cancers that kill. Quest is also conducting a phase I
clinical trial for the treatment of prostate cancer, with its
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
SOURCE Quest PharmaTech Inc.